Talk:New Article Requests

Before You Submit a Proposal

• GENERAL GUIDELINES: Your proposal should be concise, accurate, and well written. It will be reviewed by EyeWiki editors, who are practicing ophthalmologists. Spelling, grammar, and punctuation matter — your proposal reflects the quality you will bring to EyeWiki as a contributor.
  • The EyeWiki policy on AI use applies to new article proposals as well as to published content. AI tools may be used solely to improve the readability and language of your work. They may not be used to replace essential research or writing tasks, including ideation, literature review, or drafting.
• EVALUATION CRITERIA: Review these to be sure your proposal is eligible. The current acceptance rate for new articles is approximately 41%-43%.
• EXISTING ARTICLES: Review these to see if your proposed topic is already included or could be included in an existing EyeWiki article. You can do this by performing a thorough search using various related key terms.
  • If you find a pre-existing stand-alone article that addresses your topic or an article that includes your topic please edit the article to include your own input. You will be automatically recognized as a contributor to that article.
  • Of those proposals that are not accepted, 85% are rejected because the topic is already covered or could be covered in an existing EyeWiki article.
• PROPOSALS PREVIOUSLY SUBMITTED: Review these and please do not resubmit these topics. If there is substantial new evidence that has to come to light since the last proposal was rejected, you may resubmit a topic citing the new evidence to support a stand-alone EyeWiki article.
• PREAPPROVED TOPICS and ARTICLES NEEDING REVISION: Can't think of a topic for a new article? Consider revising topics on this list of articles flagged by the editorial board for revisions. Visit the discussion pages of these articles to find out what is needed. No approval is necessary to revise these articles. Currently, there are some new suggested topics that have been preapproved for stand-alone articles. Contact eyewiki@aao.org if you would like to work on one of the pre-approved new articles and can complete it within 30 days.

Instructions

• IMPORTANT: Review the section above "Before You Submit a Proposal"
• Click the "Add topic" link to create a new proposal on this page not in your own talk page.
• Then add the relevant list items as shown
  • Title: Enter this in the Subject field
  • Summary: Please provide some details about what will be covered and why you think the article would benefit EyeWiki. Do not submit a complete article. Very rarely EyeWiki editors may request additional information beyond your proposal; in most cases this is not necessary.
  • Section: Indicate what subspecialty section the article should be added to. You may indicate up to 2 sections.
  • Submitted by: Name of the ophthalmologist submitting the proposal. Sign and date your request by entering 4 tilde ~ characters only. This will automatically add your username, a time stamp and a link to your profile. You will see this after you save the page.
    • SAMPLE: Rayna.Ungersma.AAO (talk) 10:01, April 30, 2024 (PDT)
• Click: SAVE at the bottom of the page

Sample Proposal

Biosimilars in Ophthalmology
Summary: Patents for original biologics used to treat nAMD and DME are approaching expiration. Numerous companies are striving to replicate these biologics as biosimilars, which are drugs that mimic the effects of the original biologic, but do not have the same active ingredients. This article will summarize the current literature about biosimilars and their safety, efficacy, and quality and provide an in-depth review of approved biosimilars as well as those that are in development. This article will provide EyeWiki readers with information about numerous alternatives for treatment nAMD and DME.
Section: Retina/Vitreous
Submitted by: Rayna.Ungersma.AAO (talk) 15:04, May 1, 2024 (PDT)

Cognitive Bias and Diagnostic Error in Neuro-Ophthalmology

• Summary: In neuro-ophthalmology, diagnostic error, which is the failure to establish an accurate and timely explanation of the patient’s health problem, is most commonly driven by cognitive biases. This article presents four (4) cognitive biases: availability bias, self-serving bias, affective bias, and anchoring bias. System-level factors also contribute to neuro-ophthalmic diagnostic errors, such as: time pressure, volume demands, referral framing, and electronic health record (EHR) design limitations. In modern neuro-ophthalmic literature, diagnostic error is measured in two (2) ways: diagnostic label failure, which evaluates the accuracy of the initial diagnosis compared to the final diagnosis given by a fellowship trained neuro-ophthalmologist, and patient harm rate, which quantifies the harmful clinical consequences of the error (e.g., permanent/progressive vision loss, adverse effects from unnecessary treatments, or unnecessary invasive procedures). Notably, up to 71% of patients with optic nerve sheath meningioma (ONSM) have a history of misdiagnosis in neuro-ophthalmic patient care settings. Through a retrospective evaluation of clinical cases in the neuro-ophthalmology department of Houston Methodist Hospital, this article reviews biases corresponding to each case vignette and suggests potential mitigation strategies for each. A summary table linking each bias to its respective clinical case and mitigation strategy is provided in the conclusion to offer practical strategies to reduce diagnostic error to the neuro-ophthalmologists in practice.
• Section: Neuro-ophthalmology/Orbit
• Submitted by: Safa.Ibrahim (talk) 02:02, July 1, 2026 (PDT)

Veligrotug

Veligrotug-vvze (Lumvoa) recently received US FDA approval on June 26, 2026, for the treatment of thyroid eye disease, making it the second approved IGF-1R antagonist after teprotumumab and the first with labeling covering both active and chronic disease. As a full antagonist to IGF-1R, veligrotug is mechanistically distinct from teprotumumab's partial antagonism and is dosed as five infusions over 12 weeks, a shorter course than teprotumumab's eight infusions over roughly 21 weeks.

This dedicated EyeWiki article on Veligrotug will be a comprehensive entry covering: (1) summarizing the mechanism of action and IGF-1R biology in TED pathogenesis, (2) pharmacology and dosing of veligrotug, (3) key clinical trial data from THRIVE and THRIVE-2 in active and chronic TED, (4) safety and adverse effect profile, and (5) a comparison to teprotumumab and other medications to help clinicians understand where each agent fits. The article would sit alongside the existing thyroid eye disease and teprotumumab pages, providing readers with a direct comparison between the two approved IGF-1R antagonists. The article will aim to provide clinicians and researchers with detailed information on Veligrotug in a dedicated article, as it is increasingly prescribed and adopted in ophthalmology and oculoplastics.

Section: Oculoplastics/Orbit

Submitted by: Bruce.B.Becker (talk) 14:19, July 1, 2026 (PDT)